• Energenesis Biomedical (TWSE: 6657) presented at TASTI 2026 on Nov. 8 under the title “ATP: Powering Human Health Beyond Earth,” in its first move into space biomedicine.
• The company is committed to developing an innovative solution for Space Anemia, a health risk for astronauts on long-duration missions.
• Experimental results indicate that ENERGI, the company’s proprietary small-molecule platform, raises cellular ATP and may help prevent red blood cell loss in simulated extreme space environments.

TAIPEI, Nov. 9, 2026 /PRNewswire/ — Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biopharmaceutical company focused on restoring cellular energy, announced that it presented at the Taiwan Space International Conference & Industry Expo (TASTI 2026), which runs from Nov. 8-11, 2026, at the International Convention Center in Tainan, Taiwan. This year’s theme is “Trusted in Space, Resilient on Earth.” The company’s presentation, “ATP: Powering Human Health Beyond Earth,” introduced its commitment to developing an innovative solution for Space Anemia, a condition associated with accelerated red blood cell destruction in microgravity.

The challenge: Space Anemia

As commercial spaceflight expands and agencies prepare for missions to the Moon and Mars, the physiological effects of microgravity are a growing concern. A 2022 study of 14 astronauts on six-month space missions, published in Nature Medicine, found that their bodies destroyed about 54% more red blood cells in space than on Earth [1]. Prof. Yi-Chiung Hsu of National Central University (NCU), which hosted the TASTI forum on space biomedicine, said that microgravity, radiation exposure and circadian-rhythm disruption may affect the immune system, cardiovascular function, bone metabolism and muscle strength, and that integrating biomedicine, engineering and artificial intelligence to build effective health monitoring and protection is an important challenge for future deep-space exploration [2].

The approach: raising cellular ATP with ENERGI

Dr. Han-Min Chen, chairman and CEO of Energenesis Biomedical, spoke in the forum session “Beyond Earth, Beyond Limits: Innovations in Space Biomedicine and Human Health”.

In the presentation, Energenesis reported experimental results indicating that ENERGI replenishes adenine, a molecule naturally present in human cells. This activates AMPK, a key enzyme that regulates cellular energy, and raises cellular ATP. In simulated extreme space environments, the company reported that higher ATP levels in red blood cells and surrounding cells were associated with greater red blood cell stability and resilience.

“Astronauts depend on their cells having enough energy to stay healthy on long missions,” said Dr. Han-Min Chen. “Energenesis has built the approach on increasing cellular ATP to help damaged cells repair themselves. Our work on Space Anemia is a natural extension of that science, and we look forward to engaging with the global space medicine community.”

Benefits beyond space

The mechanism studied for Space Anemia may also be applied to clinical medicine on Earth. For the many patients who experience red blood cell loss and muscle atrophy due to prolonged bed rest, aging or critical illness, ENERGI’s approach of raising cellular ATP to support the body’s own cell repair may offer a promising new option for prevention and treatment.

About ENERGI

ENERGI is Energenesis Biomedical’s proprietary small-molecule platform. It is designed to restore cellular energy by increasing cellular ATP, thereby supporting the body’s own repair processes. Applications in development include ENERGI-F703DFU (topical gel for Diabetic foot ulcers, Phase III), ENERGI-F705PD (oral tablet for Parkinson’s disease, Phase I), ENERGI-F701 (tonic for Alopecia, Phase II completed), ENERGI-F703EB (cream for Epidermolysis bullosa, preparing for Phase II) and exploratory research in Space Anemia. ENERGI products are investigational and have not been approved by any regulatory authority.

About Energenesis Biomedical

Energenesis Biomedical Co., Ltd. (TWSE: 6657) is a clinical-stage biopharmaceutical company developing therapeutics that restore cellular energy and activate intrinsic repair. The company combines proprietary small-molecule research with AI-driven drug repurposing and focuses on chronic wounds, neurodegenerative diseases and rare disorders. Learn more at https://energenesis-biomedical.com/en.

Forward-Looking Statements

This press release contains forward-looking statements, including statements about the potential of ENERGI to address Space Anemia and other conditions, and future research and development activities. These statements involve risks and uncertainties, including those related to research outcomes, regulatory requirements, funding and collaboration arrangements, and actual results may differ materially. Experimental results do not guarantee clinical efficacy or safety in humans. Energenesis Biomedical undertakes no obligation to update these statements except as required by law.

Media & Business Development Contact

Business Development Team, Energenesis Biomedical Co., Ltd.
partnership@energenesis-biomedical.com

Reference

[1] Trudel, G., Shahin, N., Ramsay, T. et al. Hemolysis contributes to anemia during long-duration space flight. Nat Med 28, 59–62 (2022). https://doi.org/10.1038/s41591-021-01637-7 

[2] National Central University. Beyond Earth, Beyond Limits: NCU’s TASTI 2026 Space Biomedicine and Human Health Forum. NCU News Network, Nov. 9, 2026. https://ncusec.ncu.edu.tw/news/headlines_content.php?H_ID=4797 

View original content to download multimedia:https://www.prnewswire.com/news-releases/energenesis-biomedical-presents-energi-based-approach-to-space-anemia-at-tasti-2026-302933425.html

SOURCE Energenesis Biomedical Co., Ltd.